| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-05-0166 |
| P698 | PubMed publication ID | 15958633 |
| P2093 | author name string | John Laterra | |
| Roger Abounader | |||
| Shuli Xia | |||
| Bachchu Lal | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | glioblastoma | Q282142 |
| P304 | page(s) | 4479-4486 | |
| P577 | publication date | 2005-06-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation | |
| P478 | volume | 11 |
| Q30427677 | A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma |
| Q58164878 | A positive feedback loop between hepatocyte growth factor receptor and β-catenin sustains colorectal cancer cell invasive growth |
| Q30428363 | An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth |
| Q37129915 | Antiangiogenic therapy in brain tumors |
| Q89174882 | Bioreducible Polymeric Nanoparticles Containing Multiplexed Cancer Stem Cell Regulating miRNAs Inhibit Glioblastoma Growth and Prolong Survival |
| Q36464716 | C-MET overexpression and amplification in gliomas |
| Q41712375 | Cancer: a profit-driven biosystem? |
| Q55463914 | Caspase-3 and Bcl-2 expression in glioblastoma: an immunohistochemical study. |
| Q54977810 | Combined c-Met/Trk inhibition overcomes resistance to CDK4/6 inhibitors in Glioblastoma. |
| Q36280796 | Complex Oncogenic Signaling Networks Regulate Brain Tumor‐Initiating Cells and Their Progenies: Pivotal Roles of Wild‐Type EGFR, EGFRvIII Mutant and Hedgehog Cascades and Novel Multitargeted Therapies |
| Q24606703 | Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation |
| Q34111103 | DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation. |
| Q34198905 | Development of c-MET pathway inhibitors |
| Q33756853 | EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. |
| Q30514025 | EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase |
| Q37209597 | Expression and prognostic relevance of MET and phospho-BAD in non-small cell lung cancer |
| Q35587212 | HIF-1α contributes to proliferation and invasiveness of neuroblastoma cells via SHH signaling |
| Q44785670 | Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. |
| Q38896220 | High levels of c-Met is associated with poor prognosis in glioblastoma |
| Q39936383 | Immunohistochemical localization of caspase-3, caspase-9 and Bax in U87 glioblastoma xenografts |
| Q37312752 | Impact of MACC1 on human malignant glioma progression and patients' unfavorable prognosis |
| Q39404792 | Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation |
| Q36730368 | In Vivo c-Met Pathway Inhibition Depletes Human Glioma Xenografts of Tumor-Propagating Stem-Like Cells |
| Q30437740 | Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy |
| Q36746959 | Ionizing radiation in glioblastoma initiating cells. |
| Q36452206 | Krüppel-like family of transcription factor 9, a differentiation-associated transcription factor, suppresses Notch1 signaling and inhibits glioblastoma-initiating stem cells |
| Q33747559 | Lipid metabolism enzyme ACSVL3 supports glioblastoma stem cell maintenance and tumorigenicity |
| Q34972637 | MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint Arrest |
| Q48498498 | MET Signaling Regulates Glioblastoma Stem Cells |
| Q37458626 | MET inhibition overcomes radiation resistance of glioblastoma stem-like cells |
| Q38089834 | Malignant glioma drug discovery – targeting protein kinases |
| Q36804501 | Microarray-Based Phospho-Proteomic Profiling of Complex Biological Systems. |
| Q36828371 | Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy |
| Q37974367 | Molecularly targeted therapy in neuro-oncology |
| Q39930556 | Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models |
| Q35188319 | PTEN reconstitution alters glioma responses to c-Met pathway inhibition. |
| Q52147579 | Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients |
| Q64296860 | Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors |
| Q34983997 | Profiling the dynamics of a human phosphorylome reveals new components in HGF/c-Met signaling. |
| Q38089921 | Prognostic markers of astrocytoma: how to predict the unpredictable? |
| Q46170165 | Prognostic significance of c-Met expression in glioblastomas |
| Q38431453 | Radiation therapy for glioma stem cells |
| Q26752579 | Radioresistance of Brain Tumors |
| Q34293078 | Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102 |
| Q37368256 | Receptor signaling as a regulatory mechanism of DNA repair |
| Q90537630 | Receptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC |
| Q36700030 | Regulation of Glioblastoma Tumor-Propagating Cells by the Integrin Partner Tetraspanin CD151. |
| Q37640483 | Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition. |
| Q93033479 | Responses to crizotinib can occur in c-MET overexpressing nonsmall cell lung cancer after developing EGFR-TKI resistance |
| Q39428273 | Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma |
| Q35200337 | Role of HGF/MET axis in resistance of lung cancer to contemporary management |
| Q24683896 | Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis |
| Q39098665 | Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor. |
| Q37539304 | Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors |
| Q35078950 | The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response-Biological and Clinical Aspects |
| Q39760115 | The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells |
| Q48635543 | The clinical value of serum hepatocyte growth factor levels in patients undergoing primary radiotherapy for glioma: effect on progression-free survival |
| Q36720868 | The concurrent chemoradiation paradigm--general principles |
| Q30436756 | Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor |
| Q38083967 | Understanding the functions of tumor stroma in resistance to ionizing radiation: Emerging targets for pharmacological modulation |
| Q34232635 | Wnt activation is implicated in glioblastoma radioresistance |
| Q36544112 | Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells |
Search more.